Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-08-13

Clinical Trial Update: Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 long-term extension study of Tapinarof 1% cream for atopic dermatitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tapinarof Cream 1% (tapinarof)

Snippet

Sponsor: Organon and Co | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2025-08-13